280771-82-6Relevant articles and documents
LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
-
Paragraph 0791, (2017/04/28)
The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA
-
Page/Page column 26, (2011/10/03)
The invention relates to a new class of compounds, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions that are effective as selective inhibitors of factor Xa, both in the isolated state and in a complex with other proteins. The compounds of the invention can be used for treating and preventing diseases, such as acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, thromboses caused by post-thrombolytic therapy or coronary angioplasty, acute ischemia mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, and other diseases in humans and other mammals associated with blood coagulation problems.
Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors
Ye, Bin,Arnaiz, Damian O.,Chou, Yuo-Ling,Griedel, Brian D.,Karanjawala, Rushad,Lee, Wheeseong,Morrissey, Michael M.,Sacchi, Kama L.,Sakata, Steven T.,Shaw, Kenneth J.,Wu, Shung C.,Zhao, Zuchun,Adler, Marc,Cheeseman, Sarah,Dole, William P.,Ewing, Janice,Fitch, Richard,Lentz, Dao,Liang, Amy,Light, David,Morser, John,Post, Joseph,Rumennik, Galina,Subramanyam, Babu,Sullivan, Mark E.,Vergona, Ron,Walters, Janette,Wang, Yi-Xin,White, Kathy A.,Whitlow, Marc,Kochanny, Monica J.
, p. 2967 - 2980 (2008/02/07)
There remains a high unmet medical need for a safe oral therapy for thrombotic disorders. The serine protease factor Xa (fXa), with its central role in the coagulation cascade, is among the more promising targets for anticoagulant therapy and has been the